Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 19;11(1):3.
doi: 10.1007/s40203-023-00139-3. eCollection 2023.

Molecular docking/dynamics simulations, MEP analysis, bioisosteric replacement and ADME/T prediction for identification of dual targets inhibitors of Parkinson's disease with novel scaffold

Affiliations

Molecular docking/dynamics simulations, MEP analysis, bioisosteric replacement and ADME/T prediction for identification of dual targets inhibitors of Parkinson's disease with novel scaffold

Merzaka Mettai et al. In Silico Pharmacol. .

Abstract

Monoamine oxidase B and Adenosine A2A receptors are used as key targets for Parkinson's disease. Recently, hMAO-B and hA2AR Dual-targets inhibitory potential of a novel series of Phenylxanthine derivatives has been established in experimental findings. Hence, the current study examines the interactions between 38 compounds of this series with hMAO-B and hA2AR targets using different molecular modeling techniques to investigate the binding mode and stability of the formed complexes. A molecular docking study revealed that the compounds L24 ((E)-3-(3-Chlorophenyl)-N-(4-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl) phenyl) acrylamide and L32 ((E)-3-(3-Chlorophenyl)-N-(3-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)phenyl)acrylamide) had a high affinity (S-score: -10.160 and -7.344 kcal/mol) with the pocket of hMAO-B and hA2AR targets respectively, and the stability of the studied complexes was confirmed during MD simulations. Also, the MEP maps of compounds 24 and 32 were used to identify the nucleophilic and electrophilic attack regions. Moreover, the bioisosteric replacement approach was successfully applied to design two new analogs of each compound with similar biological activities and low energy scores. Furthermore, ADME-T and Drug-likeness results revealed the promising pharmacokinetic properties and oral bioavailability of these compounds. Thus, compounds L24, L32, and their analogs can undergo further analysis and optimization in order to design new lead compounds with higher efficacy toward Parkinson's disease.

Supplementary information: The online version contains supplementary material available at 10.1007/s40203-023-00139-3.

Keywords: ADME-T; Bioisosteric replacement; MEP maps; Molecular docking/dynamics; Parkinson’s disease; Phenylxanthine derivatives.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Scheme 1
Scheme 1
General protocol of calculation steps, as well as the methods used in the study
Fig. 1
Fig. 1
Validation of molecular docking protocol by re-docking; a SAF into the MOA-B, b XAC into the hA2AAR
Fig. 2
Fig. 2
2D Visualization of the binding modes of the best compounds L9, L10, L24, and SAF inside the active site of hMAO-B target
Fig. 3
Fig. 3
2D Visualization of the binding modes of the best compounds L5, L14, L32, and XAC inside the active site of hA2AAR target
Fig. 4
Fig. 4
The compound 24; docked (pink) well into the binding site of hMAO-B and has the highest dock score; there is also a clear difference between the final ligand pose and the docking pose (green) after a molecular dynamics (MD) (pink) simulation in NVT
Fig. 5
Fig. 5
The compound 32; docked (yellow) well into the binding site of hA2AR and has the highest dock score; there is also a clear difference between the final ligand pose and the docking pose (red) after a molecular dynamics (MD) (yellow) simulation in NVT
Fig. 6
Fig. 6
Results of molecular dynamics simulation of hMAO-B-L24 docked complex. a Eigenvalue, b variance (red color indicates individual variances and green color indicates cumulative variances), c elastic network (darker grey regions indicate stiffer regions) of the complex, d co-variance map (correlated (red), uncorrelated (white) or anti-correlated (blue) motions), e B-Factor mobility
Fig. 7
Fig. 7
Results of molecular dynamics simulation of the hA2AR-L32 docked complex. a eigenvalue, b variance (red color indicates individual variances and green color indicates cumulative variances), c elastic network (darker grey regions indicate stiffer regions) of the complex, d co-variance map (correlated (red), uncorrelated (white) or anti-correlated (blue) motions), e B-Factor mobility
Fig. 8
Fig. 8
ESP-mapped van der Waals surfaces (kcal/mol) using a color scale ranging from red (negative ESP) through white (neutral ESP) to blue (positive ESP). The blue regions are prone to nucleophilic attack, and the red regions are sites for electrophilic attack. The grid spacings were set to 0.2 Bohr, and the van der Waals surface denotes the isosurface of ρ = 0.001*e/Bohr3 (a.u). The bold numbers in the bottom right-hand corner are the positive ESP variance (PV), negative ESP variance (NV), positive surface area (A +), and negative surface area (A −) whose units are (Kcal/mol)2, Å2, respectively

Similar articles

Cited by

References

    1. Abdullah R, Basak I, Patil KS, Alves G, Larsen JP, Møller SG. Parkinson’s disease and age: the obvious but largely unexplored link. Exp Gerontol. 2015;68:33–38. doi: 10.1016/j.exger.2014.09.014. - DOI - PubMed
    1. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57:7874–7887. doi: 10.1021/jm5006463. - DOI - PubMed
    1. Azam F, Abodabos HS, Taban IM, Rfieda AR, Mahmood D, Anwar MJ, Khan S, Sizochenko N, Poli G, Tuccinardi T, Ali HI. Rutin as promising drug for the treatment of Parkinson’s disease: an assessment of MAO-B inhibitory potential by docking, molecular dynamics and DFT studies. Mol Simul. 2019;45(18):1563–1571. doi: 10.1080/08927022.2019.1662003. - DOI
    1. Bajda M, Więckowska A, Hebda M, Guzior N, Sotriffer CA, Malawska B. Structure-based search for new inhibitors of cholinesterases. Int J Mol Sci. 2013;14(3):5608–5632. doi: 10.3390/ijms14035608. - DOI - PMC - PubMed
    1. Banerjee P, Eckert AO, Schrey AK. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257–W263. doi: 10.1093/nar/gky318. - DOI - PMC - PubMed

LinkOut - more resources